# Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer

> **NCT05789667** · — · RECRUITING · sponsor: **Regina Elena Cancer Institute** · enrollment: 50 (estimated)

## Conditions studied

- Differentiated Thyroid Cancer
- Gender

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT05789667
- **Lead sponsor:** Regina Elena Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-27
- **Primary completion:** 2024-12-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05789667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05789667, "Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05789667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*